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The FAS/FASLG system plays a key role in regulating apoptosis. Previous findings have shown that CD4-
dependent destruction of melanocytes is partially inhibited by blocking FAS–FASLG interactions in autoimmune
vitiligo. Functional polymorphisms of the FAS and FASLG genes can alter their transcriptional activities. In a
hospital-based case–control study of 750 vitiligo patients and 756 controls, we genotyped the FAS1377 G4A,
FAS670 A4G, and FASLG844 T4C polymorphisms and assessed their association with the risk of vitiligo. We
found that a significantly increased risk of vitiligo was associated with the FAS1377 AA genotype (adjusted
odds ratio (OR), 1.49; 95% confidence interval (CI), 1.07–2.08) and the FAS1377 AG genotype (adjusted OR, 1.31;
95% CI, 1.05–1.63) when compared with the FAS1377 GG genotype. However, no evident risk was associated
with FAS670 G4A genotypes. In the combined analysis of the two variant alleles of FAS, genotypes with 3 to 4
risk alleles were associated with an increased risk of vitiligo compared with those having 0–2 variants (adjusted
OR, 2.87; 95% CI, 1.90–4.32). In conclusion, genetic variants in the FAS gene may affect the risk of vitiligo in
Chinese populations.
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INTRODUCTION
Vitiligo is an acquired pigmentary disorder characterized by
depigmentation of the skin and loss of epidermal melano-
cytes. Various etiologic hypotheses have been suggested; the
most compelling evidence involves a combination of
environmental, genetic, and immunologic factors whose
interactions contribute to autoimmune melanocyte destruc-
tion (Spritz 2006; Gopal et al., 2007).
FAS, also known as TNFRSF6/CD95/APO–1, is a cell
surface factor, and FASLG, also known as TNFSF6/CD95L, is
a member of the tumor necrosis factor superfamily. FAS
participates in apoptotic signaling in many types of cells
(Sharma et al., 2000), and FASLG can trigger a cell death
signal cascade by crosslinking with FAS (Kavurma and
Khachigian, 2003). Thus, the FAS/FASLG system plays a
crucial role in modulating apoptosis.
The human FAS gene, which is mapped to chromosome
10q24.1, consists of nine exons and eight introns. It has been
reported that two polymorphisms in the promoter region, a G to
A substitution at position 1377 (FAS1377 G4A, rs2234767)
in the silencer region, and an A to G substitution at position
670 (FAS670 A4G, rs1800682) in the enhancer region,
destroy the binding elements for stimulatory protein 1 and signal
transducer and activator of transcription protein 1, respectively,
thereby diminishing promoter activity and decreasing FAS
expression (Kanemitsu et al., 2002; Sibley et al., 2003). The
human FASLG gene is located on chromosome 1q23 and
comprises four exons. A polymorphism in the promoter region,
T to C substitution at position 844 (FASLG844 T4C,
rs763110), which is located within a putative binding motif of
CAAT/enhanced binding protein b transcription factor, may
cause higher basal expression of FASLG (Wu et al., 2003).
Therefore, these FAS/FASLG single-nucleotide polymorphisms
appear to be functional and might be associated with diseases in
which FAS/FASLG genes are involved.
Several studies have demonstrated that the FAS and
FASLG polymorphisms are associated with an increased risk
of autoimmune diseases, including Sjo¨gren’s syndrome
(Mullighan et al., 2004), systemic lupus erythematosus
(Nolsøe et al., 2005), autoimmune hepatitis (Agarwal et al.,
2007), and Guillain–Barre´ syndrome (Geleijns et al., 2005).
However, to the best of our knowledge, there is no reported
study on the associations between the FAS and FASLG
polymorphisms and risk of vitiligo. Previous studies suggested
the involvement of T-cell-mediated cytotoxicity and apopto-
sis in the development of vitiligo lesions (Steitz et al., 2004).
Recent findings also showed that CD4-dependent destruction
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of melanocytes is partially inhibited by blocking FAS–FASLG
interactions in an animal model of autoimmune vitiligo
(Lambe et al., 2006). As the FAS/FASLG system plays an
important role in regulating apoptosis in many cell types
including T lymphocytes, and abnormal expression of FAS
and FASLG has been observed in vitiligo (Kim et al., 2007),
we hypothesized that the functional polymorphisms in the
FAS and FASLG genes might be associated with risk of
vitiligo. To test this hypothesis, we genotyped the FAS1377
G4A, FAS670 A4G, and FASLG844 T4C polymor-
phisms in our ongoing, hospital-based case–control study of
vitiligo in Han Chinese populations.
RESULTS
Characteristics of the study population
The cases and controls appeared to be well matched
regarding age and sex: the mean age was 24.32±13.28
years for cases and 26.59±13.33 years for controls
(P¼0.165), and they had the same sex ratios (P¼0.988).
Among the cases, 5.9% had segmental vitiligo and the rest
had non-segmental vitiligo. There were 628 active (83.7%)
and 122 stable (16.3%) vitiligo patients among the cases.
Cases were considered to have a family history if they had
one or more first- to third-degree relatives afflicted with the
condition (n¼130, 17.3%). Patients were considered as
having early onset vitiligo (n¼473, 63.1%) if the age of onset
was less than 20 years (Prc´ic´ et al., 2002).
Association between FAS genotypes and risk of vitiligo
As shown in Table 1, the frequencies of the GG, AG, and AA
genotypes for the FAS1377 G4A polymorphism were 36.3,
50.4, and 13.3%, respectively, among the cases, and 43.4,
45.8, and 10.8%, respectively, among the controls. The
difference was statistically significant (P¼ 0.015). A statisti-
cally significantly increased risk of vitiligo was associated
with FAS1377 AA (adjusted OR, 1.49; 95% CI, 1.07–2.08)
and FAS1377 AG (adjusted OR, 1.31; 95% CI, 1.05–1.63),
compared with 1377 GG. The frequency of the combined
1377 A variant genotype (AGþAA) was significantly higher
among cases (63.7%) than among controls (56.6%)
(P¼0.007) and was associated with a significant increase
in risk of vitiligo (adjusted OR, 1.35; 95% CI, 1.09–1.66). For
FAS670 A4G, the frequencies of the AA, AG, and GG
genotypes among the cases were 38.0, 48.5, and 13.5%,
respectively, and 37.7, 48.1, and 14.3%, respectively, among
the controls. However, the difference was not statistically
significant (P¼ 0.899). The observed genotype frequencies of
FAS among the controls were in agreement with the
Hardy–Weinberg equilibrium (P¼ 0.514 for 1377 G4A;
and P¼ 0.660 for 670 A4G). The frequencies of the TT,
CT, and CC genotypes for FASLG844 T4C were 5.1, 33.3,
and 61.6%, respectively, among the cases, and 6.8, 33.1, and
60.1%, respectively, among the controls. However, the data
for FASLG844 were disregarded because of disagreement
with the Hardy–Weinberg equilibrium (w2-test: P¼ 0.032), so
we did not carry out further statistical analysis for this set.
Consistent with the genotypic distributions of FAS1377
G4A, the frequency of the FAS1377 variant A allele was
significantly higher among cases than among controls (0.385
and 0.337, respectively, P¼ 0.007). Similarly, the frequency
of the FAS670 variant A allele was higher among cases than
among controls (0.623 and 0.617, respectively), but the
difference was not statistically significant (P¼ 0.763). On the
basis of these data, we assumed that the minor 1377 A and
Table 1. Genotypic frequencies of FAS polymorphisms in cases and controls and their associations with risk of
vitiligo
Cases (n=750) Controls (n=756)1
Genotypes n % n % P2 Crude OR (95% CI) Adjusted OR (95% CI)3
FAS1377
GG 272 36.3 328 43.4 0.015 1.00 (reference) 1.00 (reference)
AG 378 50.4 346 45.8 — 1.32 (1.06–1.64) 1.31 (1.05–1.63)
AA 100 13.3 82 10.8 — 1.47 (1.05–2.05) 1.49 (1.07–2.08)
AG+AA 478 63.7 428 56.6 0.006 1.35 (1.09–1.66) 1.35 (1.09–1.66)
A allele — 38.5 — 33.7 0.007 — —
FAS670
GG 101 13.5 108 14.3 0.899 1.00 (reference) 1.00 (reference)
AG 364 48.5 363 48.1 — 1.07 (0.79–1.46) 1.07 (0.79–1.46)
AA 285 38.0 285 37.7 — 1.07 (0.78–1.47) 1.07 (0.78–1.47)
AG+AA 649 86.5 648 85.7 0.708 1.07 (0.80–1.44) 1.07 (0.80–1.44)
A allele — 62.3 — 61.7 0.763 — —
CI, confidence interval; OR, odds ratio.
1The observed genotype frequencies among the controls were in agreement with the Hardy–Weinberg equilibrium (w2=0.426, P=0.514 for 1377 G4A;
w2=0.194, P=0.660 for 670 A4G). Data of FASLG844 were excluded because of disagreement with the Hardy–Weinberg equilibrium (w2=4.587,
P=0.032).
2Two–sided w2-test for distributions of either genotype or allele frequencies between the cases and controls.
3ORs were obtained from a multivariate logistic regression model with adjustment for age and sex.
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670 A were putative risk alleles, which we used for the
analysis of risk associated with combined genotypes, as
described below.
Association between FAS haplotypes and combined genotype
and vitiligo risk
Further analysis showed that the two FAS polymorphisms
were in linkage disequilibrium (D0 ¼ 0.784, Po0.001),
suggesting a possible combined effect of the two FAS
polymorphisms or risk haplotypes. As shown in Table 2,
there were four possible FAS haplotypes derived from the
known genotypes, and the overall distributions of FAS
haplotypes between the cases and controls were statistically
different (Po0.001). The FASAA haplotype frequency was
significantly different between cases and controls (6.5 and
2.4%, respectively; Po0.001). Moreover, when the FASGG
haplotype was used as the reference, the AA haplotype was
associated with a significantly higher vitiligo risk (adjusted
OR, 3.29; 95% CI, 2.05–5.29). Next, we combined the two
FAS variant genotypes on the basis of the established putative
risk genotype. When the combined genotype FAS1377
(GG)/670 (AGþAA) was used as the reference, we found
that only those who carried the 1377 (AGþAA)/670
(AGþAA) genotype had a higher vitiligo risk (adjusted OR,
1.44; 95% CI, 1.15–1.79).
We obtained five genotypes according to the number of
risk alleles (that is, 1377 A and 670 A). The genotypes
with one and two variants (that is, 1377 A and 670 A)
were less common among the cases (10.1 and 77.3%,
respectively) than among the controls (13.2 and 81.9%,
respectively), and these differences were statistically signifi-
cant (Po0.001). When these five genotypes were dichoto-
mized into two groups (that is, 0–2 vs 3–4 variants) on the
basis of the number of risk alleles, their distributions differed
significantly between the cases and controls (Po0.001).
Consistently, when the genotypes with 0–2 variants were used
as the reference, it was found that the risk of vitiligo increased
significantly (adjusted OR, 2.87; 95% CI, 1.90–4.32). Finally,
we performed a stratified analysis with FAS1377 GG
genotype vs FAS1377 (AGþAA) genotype. The increased
risk was more pronounced among subgroups with the
following characteristics: age420 years (adjusted OR, 1.43;
95% CI, 1.07–1.92), female (adjusted OR, 1.53; 95% CI,
1.12–2.10), non-segmental (adjusted OR, 1.32; 95% CI,
1.07–1.62), onset agep20 years (adjusted OR, 1.36; 95%
CI, 1.05–1.77), and without family history (adjusted OR, 1.33;
95% CI, 1.07–1.65) (data not shown).
DISCUSSION
In this hospital-based case–control study, we investigated the
associations of the FAS1377 G4A, 670 A4G, and
FASLG844 T4C polymorphisms with risk of vitiligo in
Han Chinese populations. Compared with the previously
published data, our results were similar to the frequencies
found in other Chinese controls but different from the
frequencies of non–Hispanic white populations (Stuck et al.,
2003; Krippl et al., 2004; Li et al., 2006a, b), which indicated
that the genotype distributions of the FAS and FASLG
polymorphisms vary with ethnicity. Data for FASLG844
were not taken into account due to disagreement with the
Hardy–Weinberg equilibrium, most likely caused by an
insufficient number of samples, as for smaller frequencies of
the susceptibility allele in controls, a larger sample size is
needed (Hattersley and McCarthy, 2005).
The FAS670 A4G polymorphisms did not affect the
risk of vitiligo. However, we found a statistically significant
Table 2. Frequencies of the FAS haplotypes and combined genotypes among the cases and controls and their
associations with risk of vitiligo
Cases (n=1,500 alleles) Controls (n=1,512 alleles)
FAS haplotype1 n % n % P2 Crude OR (95% CI) Adjusted OR (95% CI)3
GG 86 5.8 106 7.1 0.173 1.00 (reference) 1.00 (reference)
GA 1,029 68.6 1,039 68.7 0.975 1.22 (0.91–1.64) 1.23 (0.91–1.65)
AG 287 19.1 330 21.8 0.073 1.07 (0.77–1.48) 1.08 (0.78–1.50)
AA 98 6.5 37 2.4 o0.001 3.27 (2.03–5.24) 3.29 (2.05–5.29)
Combined genotypes Cases (n=750) Controls (n=756)
n (%) n (%)
FAS1377 G4A FAS670 A4G 0.009
GG AG+AA 267 (35.6) 325 (43.0) 1.00 (reference) 1.00 (reference)
GG GG 5 (0.7) 3 (0.4) 2.03 (0.48–8.57) 2.02 (0.48–8.57)
AG+AA GG 96 (12.8) 105 (13.9) 1.11 (0.81–1.53) 1.11 (0.81–1.53)
AG+AA AG+AA 382 (50.9) 323 (42.7) 1.44 (1.16–1.79) 1.44 (1.15–1.79)
CI, confidence interval; OR, odds ratio.
1Po0.001 for the differences in haplotype allele distributions between cases and controls. Linkage disequilibrium analysis: D 0=0.784, Po0.001.
2Two-sided w2-test for distributions of either genotypic or allelic frequencies between cases and controls.
3ORs were obtained from a multivariate logistic regression model, with adjustment for age and sex.
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increased risk of vitiligo to be associated with FAS1377
G4A. In the association studies, analyzing more than one
polymorphism or more than one gene involved in the same
causal pathway appears to be more efficient than analyzing a
single polymorphism or a single gene. When we analyzed
the effects of these two FAS polymorphisms together in the
context of haplotypes, we found that the genotypes with more
than two risk alleles were associated with an increased risk of
vitiligo, suggesting that these variants may have additive
effects on the risk for this disease. When we explored the
possible effects on clinical progression of vitiligo by
FAS1377 gene polymorphisms, significantly higher vitiligo
risks were found among subgroups with the following
characteristics: age420 years, female, non-segmental, onset
agep20 years, and without family history. This suggests that
FAS1377 gene polymorphisms may have a greater effect on
these subgroups. The differences may be due to the reduction
in the number of observations in some strata or may reflect
true susceptible subgroups. Further exploration is needed to
determine whether the effects found here are an aberration,
and what the exact mechanisms underlying such effects are.
To the best of our knowledge, this is the first study
designed to investigate the associations between FAS and
FASLG polymorphisms and risk of vitiligo. The FAS receptor
is widely expressed in a variety of tissues, whereas the
expression of FASLG is restricted to the cells within the
immune system, such as activated T lymphocytes and natural
killer cells. Defective FAS function may favor autoimmunity
by slowing down cell apoptosis and/or inducing exposure of
abnormal amounts of apoptosis-related antigens (Dianzani
et al., 2003). The increased risk associated with the
FAS1377 A allele has been reported in other types of
diseases, such as acute myeloid leukemia (Sibley et al., 2003)
and cervical cancer (Lai et al., 2003). In addition, several
association studies have reported that FAS and FASLG
polymorphisms are associated with the risk of some
autoimmune diseases (Mullighan et al., 2004; Geleijns
et al., 2005; Nolsøe et al., 2005; Agarwal et al., 2007).
These studies support our finding that polymorphisms
potentially influencing the functions of FAS and FASLG are
likely to be associated with the risk of vitiligo. Stimulatory
protein 1 is an important transcriptional activator (Pugh and
Tjian, 1990), and the transcriptional activation of signal
transducer and activator of transcription 1 may depend on the
concomitant stimulatory protein 1 binding (Look et al., 1995).
The polymorphisms FAS1377 G4A and FAS670 A4G
destroy the stimulatory protein 1 and signal transducer and
activator of transcription 1 protein-binding elements, respec-
tively, and thus diminish promoter activity and decrease FAS
expression. Given the roles of the FAS/FASLG system in the
apoptosis of T lymphocytes, it is biologically plausible that
the FAS and FASLG polymorphisms may modulate the risk of
autoimmune diseases, including vitiligo. Thus, we combined
the genetic and immunologic etiology of vitiligo and
speculated that the effects of the FAS variants on risk of
vitiligo were likely due to the variant-mediated reduction in
the apoptosis of T lymphocytes, whose increasing amount led
to subsequent autoimmune destruction of melanocytes.
However, this hypothesis needs to be tested in further studies.
We also considered the possibility of polymorphic FAS
expression in melanocytes and proposed a direct effect of
high FAS expression on melanocyte apoptosis. Exactly how
the FAS variants may influence the risk of vitiligo remains
unknown, but these variants could be either functional or in
linkage disequilibrium with other, not yet tested, functional
variants involved in the etiology of vitiligo.
In summary, we provide evidence that FAS polymorph-
isms may influence the risk and clinical progression of vitiligo
in Han Chinese populations. A statistically significantly
increased risk of vitiligo was associated with the FAS1377
AA and FAS1377 AG genotypes compared with the 1377
GG genotype, but no evident risk was associated with the
FAS670 G4A polymorphism. In the combined analysis of
the two variant alleles of FAS, the genotypes with 3–4 risk
alleles were associated with an increased risk of vitiligo
compared with those having 0–2 variants. The combined risk
genotypes FAS1377 (AGþAA) were associated with a
significantly higher risk of vitiligo, which was more pro-
nounced among vitiligo patients with the following charac-
teristics: age420 years, female, non-segmental, onset
agep20 years, and without family history. Nevertheless,
better-designed and larger prospective studies are needed to
confirm these findings, and more detailed environmental
exposure data are necessary to further test potential
gene–environment interactions.
MATERIALS AND METHODS
Study population
The study subjects were recruited from Xijing Hospital between
August 2005 and January 2006. Only Han Chinese (more than 90%
of the population of China) subjects were included. The controls
were persons who came for health examinations and were
frequency-matched to the cases by age (±5 years), sex, and
ethnicity. All subjects were examined and diagnosed by dermato-
logists. We used a standard questionnaire to obtain demographic and
characteristic information. The response rate among patients and
controls approached for participation was approximately 90% for
both. Active vitiligo was defined as the appearance of new lesions or
enlargement of existing lesions in the 3 months before presentation.
After the history and clinical examination, vitiligo was classified as
segmental and non-segmental (Dave et al., 2002). Segmental vitiligo
was diagnosed if it followed a dermatomal distribution. After signing
informed consent forms, each subject donated 2ml of blood, which
was collected in heparinized tubes and used for genomic DNA
extraction. The research protocol was designed and performed
according to the Declaration of Helsinki Principles and was
approved by the ethics review board of Fourth Military University.
Genotyping
Genomic DNA was extracted from cell pellets by using a blood
genomic DNA purification kit. We used the PCR-restriction fragment
length polymorphism method to determine the FAS1377 G4A,
670 A4G, and FASLG844 T4C polymorphisms, as described
previously (Li et al., 2006a). More than 10% of the samples were
randomly selected and genotyped again by the same method to test
the discrepancy rate, and the results were 100% concordant.
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Statistical analysis
We used w2-test to evaluate the differences in frequency distributions
of selected demographic variables and each allele and genotype of
the FAS and FASLG polymorphisms between the cases and controls.
Unconditional univariate and multivariate logistic regression ana-
lyses were performed to obtain ORs for risk of vitiligo and their 95%
CIs. Multivariate adjustments were made for age and sex. The 2LD
software was used to calculate the D0 value for linkage disequili-
brium between the two FAS polymorphisms (Zapata et al., 2001;
Zhao, 2004), and the PHASE software (version 2.0.2; University of
Washington, Seattle, WA) was used to reconstruct the haplotypes
for each subject on the basis of known genotypes (Stephens et al.,
2001; Stephens and Donnelly, 2003). The association between
the combined genotypes of the FAS polymorphisms and risk of
vitiligo was also evaluated. The genotype data were further stratified
by subgroups according to age, sex, stage, type, onset age, and
family history. Statistical significance was established at a P-value of
0.05. All tests were two-sided for statistical significance and
conducted by using SAS software (version 8.2; SAS Institute
Inc., Cary, NC).
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